{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123321","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.410809+00:00","generated_at":"2026-05-30T03:25:41.989657+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kura Oncology Q3 net loss $54.4M; cash $455.3M; ziftomenib data expected early 2025","bullets":["Net loss $54.4M in Q3 2024 vs $38.6M in Q3 2023; R&D expenses $41.7M.","Cash, cash equivalents and investments $455.3M as of Sep 30, 2024; runway into 2027.","Topline results from registration-directed ziftomenib trial in R/R NPM1-mutant AML expected early 2025.","Phase 1b expansion study of ziftomenib enrolling at 600 mg; 45 patients enrolled since Aug 2024.","First patient dosed in KO-2806 + adagrasib in KRAS G12C NSCLC; GIST proof-of-concept study planned 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123321","json":"https://secwatch.observer/filing/0000950170-24-123321.json","markdown":"https://secwatch.observer/filing/0000950170-24-123321.md","text":"https://secwatch.observer/filing/0000950170-24-123321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024123321/0000950170-24-123321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024123321/kura-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:25:41.989657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}